ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 253 for:    IDARUBICIN

Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II (IDASPHERE II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02185768
Recruitment Status : Completed
First Posted : July 10, 2014
Last Update Posted : October 15, 2018
Sponsor:
Information provided by (Responsible Party):
Federation Francophone de Cancerologie Digestive

Brief Summary:

The most frequently used products in CHE are doxorubicin (36%), cisplatin (31%), and epirubicin (12%). But until recently, there were no obvious reasons to use one product over another. In fact, systemic chemotherapy is considered ineffective in HCC [hepatocellular carcinoma], which does not allow any argument in favour of the product. Moreover, 2 randomised trials comparing the molecules (doxorubicin vs. epirubicin) proved to be negative in terms of survival.

Cytotoxicity of different anticancer agents on HCC cell lines have been compared in order to select the best candidate for CHE. Eleven chemotherapy molecules have been tested, including those more frequently used in CHE. Among them, idarubicin (an anthracycline) proved to be the most effective in vitro by far. The superiority of idarubicin (as opposed to doxorubicin) was noted especially on the SNU-449 line, which is known for its resistance to several chemotherapy agents. The best cytotoxicity of idarubicin can be explained by 2 mechanisms: 1) idarubicin has a better intracellular penetration than the other anthracyclines. This is probably due to its more considerable lipophily, facilitating thus its passage through the membrane made up of a double lipid layer, 2) idarubicin is resistant to the multidrug resistance system (MDR). The MDR mechanism, which is often noted in HCC, consists of membrane pumps transporting the molecule outside the cell. These two particularities could explain a more significant accumulation of idarubicin in the HCC cells, and thus better efficacy. It is interesting to note that orally administered idarubicin (5 mg/day for 21 days) has proved to be less toxic and is effective in HCC. Currently, idarubicin is used to treat leukaemia. Its toxicity profile (especially, haematological and cardiac) is known.

On these grounds, A pilot study has been conducted in order to assess the tolerance and efficacy of lipiodol-based CHE using a 10 mg dose of idarubicin in 21 patients with unresectable HCC. These preliminary data reveal that CHE with idarubicin is effective and less toxic.

Idarubicin can be loaded in microbeads. A phase I study (IDASPHERE) has been conducted on DC Beads® microbeads (300-500µm) loaded with idarubicin (dose increased from 5 to 25 mg). The DLT [dose-limiting toxicity] and MTD [maximum tolerated dose] have been determined in 21 patients using a CRM. The MTD of idarubicin was assessed at 10 mg. In our study, the idarubicin-loaded beads did not give rise to any specific toxicity-related problem. The 10 mg dose is compatible with the known toxicity profile of idarubicin: cumulative cardiotoxicity of doxorubicin is noted from 550 mg/m², whereas that of idarubicin is noted from 93 mg/m². There is thus a 5.9:1 ratio between their cumulative toxicities. The most frequently used dose (and also the weakest one) for the doxorubicin-based CHE is 50 mg. The equivalent of the idarubicin dose would thus be: 50 mg (doxorubicin) / 5.9 (doxorubicin/idarubicin ratio) = approx. 10 mg of idarubicin.

It has been already demonstrated that hepatic extraction of idarubicin is better than those of doxorubicin and daunorubicin in an animal sarcoma model. In this study, AUC 0-48h and AUC 0-72h were 1.35 times higher with idarubicin, proving that its intra-hepatic penetration was 35% higher.

The randomised phase II PRECISION V study compared conventional CHE (cCHE) with CHE by doxorubicin beads (DC Bead®) in patients with HCC. It is currently the largest randomised trial on CHE published. The PRECISION V data can be thus used to compare the other studies in terms of efficacy and tolerance.

To continue our preliminary study and the phase I IDASPHERE study, investigators wish to assess thus the efficacy and confirm the tolerance of idarubicin-loaded beads for the CHE of HCC according to a protocol similar to PRECISION V, as part of a single-arm phase II study.


Condition or disease Intervention/treatment Phase
Liver Cancer Drug: idarubicin Device: Dc- Beads 300-500µm Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
Actual Study Start Date : January 2015
Actual Primary Completion Date : May 2018
Actual Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Arm Intervention/treatment
Experimental: DC-BEADS + Idarubicine
Chemoembolization with DC BEAD loaded with idarubicine
Drug: idarubicin
Device: Dc- Beads 300-500µm



Primary Outcome Measures :
  1. Rate of patients in objective response (complete or partial response) [ Time Frame: up to 6 months ]
    The main judgement criterion is the rate of patients in objective response (complete or partial response) at 6 months according to the mRECIST criteria and based on the central review.


Secondary Outcome Measures :
  1. Rate of patients in objective response (complete or partial response) and assessed according to the investigator. [ Time Frame: up to 6 months ]
    The rate of patients in objective response (complete or partial response) at 6 months according to the mRECIST criteria, and assessed according to the investigator.

  2. Treatment failure date [ Time Frame: up to 2 years ]

    The time interval until treatment failure This is defined by the time interval between the inclusion date and the protocol Treatment failure date. Death, progression, and any protocol treatment discontinuation (regardless of the cause) are considered as treatment failure.

    Surviving patients not subject to treatment failure will be withdrawn on the date of the last 6-month morphological assessment.


  3. Best response [ Time Frame: up to 2 years ]
    The best response according to the mRECIST criteria

  4. Survival without progression [ Time Frame: up to 2 years ]

    Survival without progression:

    This is defined by the time interval between the inclusion date and the date of the 1st progression according to the mRECIST criteria (assessed in central review) or death (regardless of the cause).

    The surviving patients without progression will be withdrawn on the date of the last recorded news


  5. Overall survival [ Time Frame: up to 2 years ]
    Overall survival This is defined by the time interval between the inclusion date and the date of death (regardless of the cause) or the date of the last recorded news for the surviving patients.

  6. Treatment tolerance [ Time Frame: up to 2 years ]
    Treatment tolerance Toxicities will be assessed using the NCI-CTC criteria v4.0. They will be described according to their degree as number of toxicities and number of patients presenting toxicity.

  7. Quality of life [ Time Frame: up to 6 months ]
    Quality of life (QLQ-C30 questionnaires and its HCC18 module specific to HCC)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • - Histologically diagnosed HCC or HCC diagnosed according to the EASL criteria
  • Measurable targets according to the mRECIST v1.1 criterion
  • Preserved liver function (in case of Child-Pugh A or B7 cirrhosis)
  • Tumour not subject to interventive care (liver transplant, surgical resection or percutaneous destruction)
  • BCLC A/B without portal or extra-hepatic invasion
  • No prior treatment by chemotherapy, radiotherapy or transarterial embolisation (with or without chemotherapy)
  • Age ≥ 18 years
  • WHO 0 or 1
  • Laboratory test: platelets ≥ 50,000 mm3, N ≥ 1,000/mm3, creatininaemia ≤ 150 µmol/L, PT ≥ 50%
  • No heart failure (isotope or ultrasound VEF > 50%)

Exclusion Criteria:

  • - Advanced tumour (vascular or extra-hepatic invasion including brain metastasis or diffuse HCC with liver invasion > 50%)
  • History of other type of cancer except cancer known to be in remission for more than 5 years (in this case, HCC histological proof is required), or basal-cell carcinoma or in situ cervix uteri cancer properly treated with curative treatment
  • Advanced liver disease (Child B8, B9 and C, bilirubinaemia > 3 mg/dL, SGOT and SGPT > 5 x ULN or 250 U/L)
  • Previous treatment by idarubicin and/or doxorubicin
  • Idarubicin contraindications (cardiopathy with myocardial failure, serious kidney or liver failure, yellow fever vaccine)
  • Concurrent disease or uncontrolled severe clinical condition
  • Uncontrolled severe infection
  • Patient requiring long-term anticoagulant treatment
  • Thrombosis of the portal vein or a 3-segment region or more
  • Hepatofugal portal venous flow
  • Presence of serious atheromatosis
  • Presence of collateral vascular ways potentially affecting the normal regions during embolisation
  • Presence of arthritis of the hepatic artery branches to be treated
  • Presence of arterioportal or arterial subhepatic fistula that cannot be embolised by coils
  • Pregnancy or breastfeeding
  • Absence of effective contraception (for men and women of childbearing age)
  • Patient who cannot be regularly monitored on account of psychological, social, family- or geography-related reasons
  • Concomitant participation of a patient in another study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02185768


Locations
France
CHU Amiens
Amiens, France
CHU d'ANGERS
Angers, France, 49933
CHU - Hôpital François Mitterand
Dijon, France, 21079
Hôpital La Croix Rousse
Lyon, France, 69317
Hôpital Edouard Herriot
Lyon, France, 69437
CHU St Eloi
Montpellier, France, 34295
Hôpital de l'Archet II
Nice, France, 06202
Sponsors and Collaborators
Federation Francophone de Cancerologie Digestive
Investigators
Principal Investigator: Boris GUIU, PhD Fédération Francophone de Cancérologie Digestive

Responsible Party: Federation Francophone de Cancerologie Digestive
ClinicalTrials.gov Identifier: NCT02185768     History of Changes
Other Study ID Numbers: FFCD 1307
First Posted: July 10, 2014    Key Record Dates
Last Update Posted: October 15, 2018
Last Verified: October 2018

Keywords provided by Federation Francophone de Cancerologie Digestive:
Liver cancer

Additional relevant MeSH terms:
Idarubicin
Carcinoma, Hepatocellular
Liver Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action